Stefani Spranger

netbet online sports betting

Howard S. and Linda B. Stern Career Development Professor; Intramural Faculty, Koch Institute

Stefani Spranger studies how the body’s immune system interacts with growing tumors to harness the immune response to fight cancer.

617-715-5882

Phone

76-453D

Office

Koch Institute for Integrative Cancer Research

Location

Judy Teixeira

Assistant

617-253-0263

Assistant Phone

Education

  • PhD, 2011, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich
  • MSc, Biology, 2008, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich
  • BSc, Biology, 2005, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich

Research Summary

We examine the interaction between cancer and immune cells. Using tumor mouse models designed to mimic tumor progression in humans, we investigate the co-evolution of the anti-tumor immune response and cancer. Understanding the interplay between tumor cells and immune cells will help develop and improve effective cancer immunotherapies.

Awards

  • Forbeck Fellow, 2015

Recent Publications

  1. Expansion of tumor-reactive CD8+ T cell clonotypes occurs in the spleen in response to immune checkpoint blockade. Morgan, DM, Horton, BL, Bhandarkar, V, Van, R, Dinter, T, Zagorulya, M, Love, JC, Spranger, S. 2024. Sci Immunol 9, eadi3487.
    doi: 10.1126/sciimmunol.adi3487PMID:39270006
  2. Mutant p53 Exploits Enhancers to Elevate Immunosuppressive Chemokine Expression and Impair Immune Checkpoint Inhibitors in Pancreatic Cancer. Mahat, DB, Kumra, H, Castro, SA, Metcalf, E, Nguyen, K, Morisue, R, Ho, WW, Chen, I, Sullivan, B, Yim, LK et al.. 2024. bioRxiv , .
    doi: 10.1101/2024.08.28.609802PMID:39257788
  3. Transforming ovarian cancer care by targeting minimal residual disease. Jazaeri, AA, Grisham, R, Knisely, A, Spranger, S, Zamarin, D, Hillman, RT, Lawson, BC, Burns, KH, Lee, S, Westin, SN et al.. 2023. Med 4, 755-760.
    doi: 10.1016/j.medj.2023.08.004PMID:37951209
  4. Overcoming lung cancer immunotherapy resistance by combining netbet sports bettingnontoxic variants of IL-12 and IL-2. Horton, BL, D'Souza, AD, Zagorulya, M, McCreery, CV, Abhiraman, GC, Picton, L, Sheen, A, Agarwal, Y, Momin, N, Wittrup, KD et al.. 2023. JCI Insight 8, .
    doi: 10.1172/jci.insight.172728PMID:37669107
  5. Decoupled neoantigen cross-presentation by dendritic cells limits anti-tumor immunity against tumors with heterogeneous neoantigen expression. Nguyen, KB, Roerden, M, Copeland, CJ, Backlund, CM, Klop-Packel, NG, Remba, T, Kim, B, Singh, NK, Birnbaum, ME, Irvine, DJ et al.. 2023. Elife 12, .
    doi: 10.7554/eLife.85263PMID:37548358
  6. Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies. Lax, BM, Palmeri, JR, Lutz, EA, Sheen, A, Stinson, JA, Duhamel, L, Santollani, L, Kennedy, A, Rothschilds, AM, Spranger, S et al.. 2023. Proc Natl Acad Sci U S A 120, e2300895120.
    doi: 10.1073/pnas.2300895120PMID:37487077
  7. A prime editor mouse to model a broad spectrum of somatic mutations in vivo. Ely, ZA, Mathey-Andrews, N, Naranjo, S, Gould, SI, Mercer, KL, Newby, GA, Cabana, CM, Rideout, WM 3rd, Jaramillo, GC, Khirallah, JM et al.. 2024. Nat Biotechnol 42, 424-436.
    doi: 10.1038/s41587-023-01783-yPMID:37169967
  8. Engineering kinetics of TLR7/8 agonist release NetBet live casinofrom bottlebrush prodrugs enables tumor-focused immune stimulation. Bhagchandani, SH, Vohidov, F, Milling, LE, Tong, EY, Brown, CM, Ramseier, ML, Liu, B, Fessenden, TB, Nguyen, HV, Kiel, GR et al.. 2023. Sci Adv 9, eadg2239.
    doi: 10.1126/sciadv.adg2239PMID:37075115
  9. Tissue-specific abundance of interferon-gamma drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer. Zagorulya, M, Yim, L, Morgan, DM, Edwards, A, Torres-Mejia, E, Momin, N, McCreery, CV, Zamora, IL, Horton, BL, Fox, JG et al.. 2023. Immunity 56, 386-405.e10.
    doi: 10.1016/j.immuni.2023.01.010PMID:36736322
  10. MHC-dressing on dendritic cells: Boosting anti-tumor immunity via unconventional tumor antigen presentation. Chatterjee, F, Spranger, S. 2023. Semin Immunol 66, 101710.
    doi: 10.1016/j.smim.2023.101710PMID:36640616
More Publications

Multimedia